A New Dosing Regimen for Nivolumab Plus Ipilimumab in Advanced Melanoma
The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Immunotherapy Combo Active in Metastatic Prostate Cancer Immunotherapy Combo Active in Metastatic Prostate Cancer
The combination of ipilimumab with nivolumab shows activity in advanced disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Concerns Raised About Patient-Reported Outcomes in CheckMate 214 Trial
An exploratory analysis showed that patients who received nivolumab plus ipilimumab had better patient-reported outcomes. Do the results hold up? (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
Mesothelioma Immunotherapy Combination Gaining Momentum
Recent studies from France and the Netherlands have shown patients with pleural mesothelioma can benefit significantly from a second-line immunotherapy drug combination.
In separate phase II studies, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) created a synergy that helped stop or slow tumor growth after traditional chemotherapy had failed.
“Our results add to the growing evidence that immunotherapy is a promising treatment,” wrote lead author Dr. Maria Disselhorst of the Netherlands Cancer Institute in Amsterdam. “The combination of nivolumab plus ipilimumab showed marked efficacy in patients with ...
Source: Asbestos and Mesothelioma News - February 11, 2019 Category: Environmental Health Authors: Daniel King Source Type: news
BMS withdraws Opdivo+Yervoy application
Bristol-Myers Squibb has withdrawn its application for FDA approval of a treatment that combined Opdivo with the drugmaker ' s other immune-oncology drug, Yervoy. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 24, 2019 Category: Pharmaceuticals Source Type: news
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ( “low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). (Source: World Pharma News)
Source: World Pharma News - January 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Talimogene laherparepvec plus ipilimumab not cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news
EU Changes Mind on Nivo Plus Ipi for Kidney Cancer EU Changes Mind on Nivo Plus Ipi for Kidney Cancer
Positive opinions were given for the first-line use of the immunotherapy combination nivolumab and ipilimumab in kidney cancer and for an extension of indication for blinatumomab in certain leukemia patients.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
This review of 36 head-to-head trials found for all adverse events, the ranking was as follows for general safety (high to low): atezolizumab, nivolumab, pembrolizumab, ipilimumab and tremelimumab. Nivolumab had the best safety profile in lung cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 14, 2018 Category: Consumer Health News Source Type: news
MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news
Radiation Could Make Mesothelioma Immunotherapy More Effective
Doctors at the Princess Margaret Cancer Center in Toronto are studying the use of hypofractionated radiation to increase the effectiveness of immunotherapy for patients with mesothelioma.
They are expected to launch soon a clinical trial that will add an immunotherapy combination to the high-dose radiation and aggressive surgery mix that has been so successful in Toronto.
“There are a lot of questions that still need to be answered, but if I was a betting man, I’d lay odds on it [working well],” Dr. John Cho of the cancer center’s clinical research unit, told The Mesothelioma Center at Asbestos.com. “It’s all v...
Source: Asbestos and Mesothelioma News - November 2, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
Nivolumab Plus Ipilimumab in Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 29, 2018 Category: Urology & Nephrology Source Type: news
